[{"id":"c67cb0cc-4062-4cc7-ac4c-e0358ba638bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06986174","created_at":"2025-06-28T16:12:40.055Z","updated_at":"2025-06-28T16:12:40.055Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT06986174","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" TP53 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-05-22"},{"id":"49601ae5-fd50-4ceb-b7f3-e357f9864917","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922724","created_at":"2021-01-18T19:17:55.581Z","updated_at":"2025-02-25T12:27:11.116Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03922724","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • HLA-B • HLA-C","pipe":" | ","alterations":" ALK positive","tags":["ALK • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • sirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-24"},{"id":"65fa5200-d596-487d-929e-1fa05dc863a1","acronym":"NRG-GY007","url":"https://clinicaltrials.gov/study/NCT02713386","created_at":"2021-01-18T13:15:58.271Z","updated_at":"2025-02-25T12:26:27.453Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02713386 - NRG-GY007","lead_sponsor":"NRG Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA • CRP","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"5a4c3655-9f33-4faa-a284-8b91e071174d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03610971","created_at":"2022-04-24T08:59:34.197Z","updated_at":"2025-02-25T14:01:30.574Z","phase":"Phase 2","brief_title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT03610971","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-19"},{"id":"5202b47d-cbbb-4824-a53c-3a13ffa0fe0a","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT05936359","created_at":"2023-07-07T14:09:44.600Z","updated_at":"2025-02-25T14:42:12.068Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05936359 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-14"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"b80fb1d9-c22f-4356-804c-6c0a54eb0ff6","acronym":"SENTRY","url":"https://clinicaltrials.gov/study/NCT04562389","created_at":"2021-01-29T07:21:26.651Z","updated_at":"2025-02-25T16:45:11.264Z","phase":"Phase 3","brief_title":"Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis","source_id_and_acronym":"NCT04562389 - SENTRY","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/11/2021","start_date":" 03/11/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-05"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"96e420b5-20d6-444c-80a7-976e582c147d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05440942","created_at":"2022-07-01T21:55:26.997Z","updated_at":"2025-02-25T15:54:31.335Z","phase":"Phase 1","brief_title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT05440942","lead_sponsor":"Peter Hosein, MD","biomarkers":" TMB • BRCA1 • BRCA2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-09-11"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"2a11f2ce-d7a1-4499-9adf-7f2d5fda7036","acronym":"ROSALINE","url":"https://clinicaltrials.gov/study/NCT04551495","created_at":"2021-01-18T21:45:49.585Z","updated_at":"2024-07-02T16:34:26.568Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)","source_id_and_acronym":"NCT04551495 - ROSALINE","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • letrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"bc4bd5fe-eb27-4217-b824-f4e3646427cd","acronym":"UPCC 02112","url":"https://clinicaltrials.gov/study/NCT01594216","created_at":"2021-01-18T06:48:41.179Z","updated_at":"2024-07-02T16:34:26.790Z","phase":"Phase 2","brief_title":"Ruxolitinib in Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01594216 - UPCC 02112","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/09/2016","study_completion_date":" 04/09/2016","last_update_posted":"2024-06-12"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"9259cd2b-7d10-4e29-a71a-448de9ccec7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257138","created_at":"2021-01-18T10:36:04.617Z","updated_at":"2024-07-02T16:35:05.273Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","source_id_and_acronym":"NCT02257138","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jakafi (ruxolitinib) • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2024-05-08"},{"id":"c41f6dcf-1a0e-427e-84b3-c66ecc85d44e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05998408","created_at":"2023-08-21T16:09:13.482Z","updated_at":"2024-07-02T16:35:06.081Z","phase":"Phase 1/2","brief_title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","source_id_and_acronym":"NCT05998408","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/20/2024","start_date":" 02/20/2024","primary_txt":" Primary completion: 06/03/2030","primary_completion_date":" 06/03/2030","study_txt":" Completion: 06/03/2032","study_completion_date":" 06/03/2032","last_update_posted":"2024-05-03"},{"id":"42d528a0-190a-487f-b179-8b27c02a354a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02876302","created_at":"2021-01-18T14:07:18.368Z","updated_at":"2024-07-02T16:35:08.935Z","phase":"Phase 2","brief_title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","source_id_and_acronym":"NCT02876302","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 01/24/2018","start_date":" 01/24/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-18"},{"id":"dcc86dfa-5f1f-487e-97bd-3b553b98917f","acronym":"STARTRK-NG","url":"https://clinicaltrials.gov/study/NCT02650401","created_at":"2021-01-18T12:54:05.938Z","updated_at":"2024-07-02T16:35:12.285Z","phase":"Phase 1/2","brief_title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","source_id_and_acronym":"NCT02650401 - STARTRK-NG","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-29"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"9b0dc769-7e69-4597-ba4b-209925af9306","acronym":"","url":"https://clinicaltrials.gov/study/NCT02891603","created_at":"2021-01-18T14:11:34.890Z","updated_at":"2024-07-02T16:35:12.946Z","phase":"Phase 1/2","brief_title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","source_id_and_acronym":"NCT02891603","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 04/18/2022","study_completion_date":" 04/18/2022","last_update_posted":"2024-03-25"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"3256127a-0abe-4b2e-b192-b4bbda0ec654","acronym":"","url":"https://clinicaltrials.gov/study/NCT01594723","created_at":"2021-01-18T06:48:50.034Z","updated_at":"2024-07-02T16:35:13.492Z","phase":"Phase 2","brief_title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01594723","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2012","start_date":" 05/22/2012","primary_txt":" Primary completion: 03/20/2015","primary_completion_date":" 03/20/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-21"}]